# A Study of LY3537021 in Healthy Participants

> **NCT05444569** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 47 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY3537021
- **DRUG:** Liraglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05444569
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-08
- **Primary completion:** 2023-02-24
- **Final completion:** 2023-02-24
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05444569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05444569, "A Study of LY3537021 in Healthy Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05444569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*